Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib roll-over study for patients benefitting from prior Novartis nilotinib trials
jRCT2080222142Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Jul 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2080222142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222142.